An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma

Abstract excerpt

BACKGROUND: While some lung adenocarcinoma (LUAD) patients benefit long-term from treatment with immune checkpoint inhibitors, the sad reality is that a considerable proportion of patients do not. The classification of the LUAD tumor microenvironment (TME) can be used to conceptually comprehend primary resistance mechanisms. In addition, the most recent research demonstrates that the release of damage-associated...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Immunotherapy and Biomarkers
• Share to Ferroptosis and cancer prognosis
• Share to Inflammatory Biomarkers in Disease Prognosis